Tyrogenex

CompanyUnited States

Tyrogenex develops one asset, in phase 2, discontinued (X-82 in age-related macular degeneration). Mostly small molecule acting on PDGFRB, PDGFRA and FLT1; based in the United States.

1
Asset
Furthest stage
Phase 2, discontinued
3
Trials
0
Signals

Pipeline

1
  • X-82

    Dual inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor kinases

    Phase 2, discontinued, Small molecule, PDGFRB, PDGFRA, age-related macular degeneration, exudative age-related macular degeneration

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms5
  • Trials5
  • Similar companies6

Intelligence